Efficacy and safety study of a new synthetic 10-component, modified release conjugated estrogens (CE) tablet for treatment of vasomotor symptoms in postmenopausal women

2002 ◽  
Vol 78 ◽  
pp. S159 ◽  
Author(s):  
Wulf H Utian ◽  
Thomas W Leonard ◽  
Angela D Davis ◽  
Rhonda Y Vega
Keyword(s):  
Postmenopausal Women ◽  
Vasomotor Symptoms ◽  
Modified Release ◽  
Efficacy And Safety ◽  
Safety Study ◽  
Conjugated Estrogens

scholarly journals The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Stefano Lello ◽  
Anna Capozzi ◽  
Giovanni Scambia
Keyword(s):  
Postmenopausal Women ◽  
Endometrial Hyperplasia ◽  
Vasomotor Symptoms ◽  
Line Treatment ◽  
Vaginal Atrophy ◽  
First Line ◽  
Conjugated Estrogens ◽  
Receptor Modulator ◽  
First Line Treatment

The tissue-selective estrogen complex (TSEC) pairs conjugated estrogens (CE) with a selective estrogen receptor modulator (SERM), bazedoxifene acetate (BZA). A 2-year treatment with the TSEC improved vasomotor symptoms, quality of life, and vaginal atrophy in healthy postmenopausal women. In addition, the TSEC prevented vertebral and hip bone loss without increasing mammographic density, breast tenderness, the risk of myocardial infarction, stroke, or venous thromboembolism. Finally, the BZA 20 mg/CE 0.45 mg dose did not increase the risk of endometrial hyperplasia. Based on these findings, the TSEC can be considered as a first-line treatment for symptomatic postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document